The study centers on ATX-01, an investigational antimiR-23b therapy developed by the Valencia-based company ARTHEx Biotech. By utilizing their proprietary BOOST-ON platform, researchers successfully delivered the therapeutic intravenously, allowing it to penetrate the central nervous system. Once inside, the treatment increased MBNL1/2 protein levels and reduced toxic DMPK transcripts, which are the primary drivers of the multisystemic disorder.
ARTHEx Biotech Data Links Brain Correction to Behavior in DM1 Model
A new preclinical study published in Cell Reports Medicine provides the first evidence that systemic delivery of an RNA therapeutic can cross the blood-brain barrier to reverse behavioral deficits in Myotonic Dystrophy Type 1, marking a potential breakthrough for patients suffering from the disease’s neurological manifestations.
Beyond molecular correction, the data demonstrated a functional improvement in an animal model, specifically normalizing exploratory behaviors previously altered by the disease. Beatriz Llamusí, Chief Scientific Officer at ARTHEx, noted that this research establishes a vital bridge between correcting cellular defects and achieving meaningful functional recovery. While the company is currently evaluating ATX-01 in the Phase I/IIa ArthemiR clinical trial with an initial focus on muscle and systemic symptoms, these findings suggest the platform may eventually address the broader spectrum of DM1, including the cognitive impairment and behavioral changes that remain significant unmet needs for patients.
Comments (0)
No comments yet. Be the first!